SCHEMBL7708220

SCHEMBL7708220

CC1Oc2ccc(C(Cc3cccc(C(F)(F)F)c3)NC(=O)OC(C)(C)C)cc2NC1=O

nearest known ligand 0.41

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PARP1 P09874 1/20 0.41
SCN9A Q15858 1/20 0.41
PTPRB P23467 1/20 0.39
FAAH O00519 1/20 0.38
HDAC1 Q13547 1/20 0.36
HDAC6 Q9UBN7 1/20 0.36
HDAC5 Q9UQL6 1/20 0.36
CCKAR P32238 1/20 0.36
CCKBR P32239 1/20 0.36
IDO1 P14902 1/20 0.36
RORC P51449 9/20 0.36
JAK2 O60674 1/20 0.36
ALDH1A1 P00352 1/20 0.36
TP53 P04637 1/20 0.36
HPGD P15428 1/20 0.36
MAPK1 P28482 1/20 0.36
HTT P42858 1/20 0.36
ATM Q13315 1/20 0.36
NPSR1 Q6W5P4 1/20 0.36
HSD17B10 Q99714 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7091516 0.91 SCN9A (0.39) SCN9APTPRBFAAHHDAC1HDAC6
SCHEMBL7713251 0.90 CTSS (0.45) PARP1SCN9ACCKARCCKBRIDO1
SCHEMBL7713374 0.89 PARP1 (0.50) PARP1CCKARCCKBRIDO1JAK2
SCHEMBL7711091 0.88 PARP1 (0.42) PARP1CCKARCCKBRIDO1ALDH1A1
SCHEMBL7711137 0.88 CTSL (0.45) PARP1SCN9ACCKARCCKBRIDO1
SCHEMBL7708144 0.85 PARP1 (0.42) PARP1SCN9ACCKARCCKBRIDO1
SCHEMBL7713283 0.85 PARP1 (0.40) PARP1CCKARCCKBRIDO1ALDH1A1
SCHEMBL7713294 0.85 PARP1 (0.42) PARP1CCKARCCKBRIDO1JAK2
SCHEMBL7713423 0.84 PARP1 (0.41) PARP1CCKARCCKBRIDO1ALDH1A1
SCHEMBL7713338 0.84 PARP1 (0.42) PARP1CCKARCCKBRIDO1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-6365736-B1 TREATMENT OF NERVOUS SYSTEM DISORDERS, CARDIOVASCULAR DISORDERS AND FOR ACTIVITY AS NO-SYNTHASES (NOS) INHIBITORS. SCHERING AKTIENGESELLSCHAFT (DE) 2002-04-02 US disclosed